Robert B.  Bazemore Jr. net worth and biography

Robert Bazemore Jr. Biography and Net Worth

CEO of Epizyme
Robert B. Bazemore Jr. serves as President, Chief Executive Officer, Director of the Company. Prior to joining us, from September 2014 to July 2015, Mr. Bazemore served as the Chief Operating Officer of Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare disorders. Prior to joining Synageva, Mr. Bazemore served in increasing levels of responsibility at Johnson & Johnson, a healthcare company, including Vice President, Centocor Ortho Biotech Sales & Marketing from 2008 to 2010, President of Janssen Biotech from March 2010 to October 2013 and Vice President of Global Surgery at Ethicon from October 2013 to September 2014. Prior to Johnson & Johnson, Mr. Bazemore worked at Merck & Co., Inc. for eleven years, where he served in a variety of roles in medical affairs, sales and marketing. Mr. Bazemore is a director of Ardelyx, Inc., a biopharmaceutical company. He received a B.S. in biochemistry from the University of Georgia.

What is Robert B. Bazemore Jr.'s net worth?

The estimated net worth of Robert B. Bazemore Jr. is at least $488,006.19 as of February 4th, 2021. Mr. Bazemore Jr. owns 331,977 shares of Epizyme stock worth more than $488,006 as of March 28th. This net worth evaluation does not reflect any other assets that Mr. Bazemore Jr. may own. Learn More about Robert B. Bazemore Jr.'s net worth.

How do I contact Robert B. Bazemore Jr.?

The corporate mailing address for Mr. Bazemore Jr. and other Epizyme executives is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. Epizyme can also be reached via phone at (617) 229-5872 and via email at [email protected]. Learn More on Robert B. Bazemore Jr.'s contact information.

Has Robert B. Bazemore Jr. been buying or selling shares of Epizyme?

Robert B. Bazemore Jr. has not been actively trading shares of Epizyme during the last quarter. Learn More on Robert B. Bazemore Jr.'s trading history.

Who are Epizyme's active insiders?

Epizyme's insider roster includes Shefali Agarwal (Insider), Robert Bazemore Jr. (CEO), Joseph Beaulieu (Insider), Jeffery Kutok (Insider), Pablo Legorreta (Director), and David Mott (Director). Learn More on Epizyme's active insiders.

Robert B. Bazemore Jr. Insider Trading History at Epizyme

See Full Table

Robert B. Bazemore Jr. Buying and Selling Activity at Epizyme

This chart shows Robert B. Bazemore's buying and selling at Epizyme by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Epizyme Company Overview

Epizyme logo
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $1.47
Low: $1.47
High: $1.47

50 Day Range

MA: $1.47
Low: $1.47
High: $1.52

2 Week Range

Now: $1.47
Low: $0.41
High: $5.80

Volume

7,960 shs

Average Volume

3,225,203 shs

Market Capitalization

$247.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A